^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers
Published date:
05/15/2020
Excerpt:
HER2 was the most commonly amplified gene in EG cancers (14.1%) and was also amplified in 2.4% of ovarian cancers. HER2 mutations occurred in 6.1% of EG and 1.5% ovarian cancers. All five cell lines tested displayed nanomolar sensitivity to single agent neratinib or dasatinib (Table). The combination of neratinib and dasatinib was synergistic in all cell lines...These data suggest that the addition of dasatinib may enhance the anti-cancer effect of neratinib in HER2-driven ovarian and EG cancers and warrants further investigation.
DOI:
10.1158/1538-7445.AM2020-1773
